



## Acute Myeloid Leukemia: From Pathophysiology to Novel Therapeutic Approaches

Guest Editors:

**Prof. Dr. Rotraud Wieser**

Clinic of Medicine I, and  
Comprehensive Cancer Center,  
Medical University of Vienna,  
Vienna, Austria

**Dr. Giorgia Simonetti**

IRCCS Istituto Romagnolo per lo  
Studio dei Tumori (IRST) “Dino  
Amadori”, Meldola, FC, Italy

**Dr. Felicetto Ferrara**

Dipartimento Onco-ematologico  
e pneumoematologico, Azienda  
Ospedaliera Di Rilievo Nazionale  
Antonio Cardarelli, Naples, Italy

Deadline for manuscript  
submissions:

**closed (30 November 2021)**

### Message from the Guest Editors

Dear Colleagues,

This Special Issue, entitled "Acute Myeloid Leukemia: From Pathophysiology to Novel Therapeutic Approaches", will mainly focus on understanding the factors that drive tumor progression and will assess the introduction of selective pathway inhibitors that tackle AML progression.

The outcome for patients with AML is improving as a result of combined efforts in academic and industrial research that introduced several new therapies, some of which are specifically addressed toward the inhibition of pathways involved in leukemogenesis.

We invite authors to submit original research and review articles that focus on the pathophysiology and new therapeutic strategies for AML. Potential topics include, but are not limited to:

- Molecular pathogenesis of AML
- Prognostic stratification
- The role of MRD
- New agents for AML
- New immunotherapeutic approaches
- The current role of allogeneic stem cell transplantation

Dr. Felicetto Ferrara  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)